AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

60.24USD
24 Oct 2014
Price Change (% chg)

$0.72 (+1.21%)
Prev Close
$59.52
Open
$59.62
Day's High
$60.40
Day's Low
$59.60
Volume
1,781,254
Avg. Vol
2,321,631
52-wk High
$60.40
52-wk Low
$45.51

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $96,069.21
Shares Outstanding (Mil.): 1,593.45
Dividend: 0.49
Yield (%): 3.25

Financials

  ABBV.N Industry Sector
P/E (TTM): 23.26 33.21 34.06
EPS (TTM): 2.59 -- --
ROI: 19.03 18.18 17.45
ROE: 95.03 18.85 18.26
Search Stocks

UPDATE 1-Jilted Shire raises guidance again after Q3 earnings jump

LONDON, Oct 24 - Pharmaceutical firm Shire raised its guidance for full-year earnings on Friday, underlining its strong prospects as a standalone company after AbbVie Inc officially ditched its $55 billion purchase of the group on Tuesday.

24 Oct 2014

Jilted Shire raises guidance again after Q3 earnings jump

LONDON, Oct 24 - Pharmaceutical firm Shire raised its guidance for full-year earnings on Friday, underlining its strong prospects as a standalone company after AbbVie Inc officially ditched its $55 billion purchase of the group on Tuesday.

24 Oct 2014

AbbVie says $55 billion acquisition of Shire officially dead

- U.S. drugmaker AbbVie Inc said on Monday it has reached agreement with Shire Plc to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away from the deal.

21 Oct 2014

AbbVie CEO Gonzalez loses Shire, but wins praise for gutsy move

NEW YORK - (This story has been refiled from the Oct. 20 story to fix a typo in the headline)

21 Oct 2014

REFILE-RPT-AbbVie CEO Gonzalez loses Shire, but wins praise for gutsy move

NEW YORK, Oct 20 - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker.

21 Oct 2014

REFILE--AbbVie CEO Gonzalez loses Shire, but wins praise for gutsy move

NEW YORK, Oct 20 - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker.

21 Oct 2014

Deals of the day- Mergers and acquisitions

Oct 21 - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:

21 Oct 2014

CORRECTED-AbbVie CEO Gonzalez loses Shire, but wins praise for gusty move

NEW YORK, Oct 20 - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker.

21 Oct 2014

AbbVie says $55 billion acquisition of Shire officially dead

- U.S. drugmaker AbbVie Inc said on Monday it has reached agreement with Shire Plc to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away from the deal.

21 Oct 2014

UPDATE 1-AbbVie says $55 billion acquisition of Shire officially dead

(Adds CEO comment, background, share repurchase, share price)

21 Oct 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.04 +0.41
Pfizer Inc. (PFE.N) $29.12 +0.52
Novartis AG (NOVN.VX) CHF85.75 +0.35
Merck & Co., Inc. (MRK.N) $57.63 +1.00
Roche Holding Ltd. (ROG.VX) CHF278.00 -1.40
Abbott Laboratories (ABT.N) $42.45 +0.02
Eli Lilly and Co (LLY.N) $66.06 +1.71

Earnings vs. Estimates

Search Stocks